Beam Therapeutics attracts $87 mln Series A
Cambridge, Massachusetts-based Beam Therapeutics, a developer of precision genetic medicines through base editing, has raised up to $87 million in Series A funding. F-Prime Capital Partners and ARCH Venture Partners led the round.
14 May 2018•1 min read
